AI Insight: Alnylam's current price exceeds the PERT-weighted fair value by 24.9%, indicating potential overvaluation despite strong liquidity, profitability, and growth scores. The wide valuation range, driven by high analyst target estimates, suggests differing market expectations. Zero Monte Carlo downside scenarios highlight low near-term price risk but underscore valuation uncertainty.